Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID‐19 patients

Pharmacology Research and Perspectives - Tập 8 Số 4 - 2020
Bruce M. Hendry1, Nina Stafford2, Ahran Arnold3, Arvind Sangwaiya2, Vijay Manglam2, Stuart D. Rosen3, Jayantha Arnold2
1Renal Sciences, Department of Inflammation Biology, King’s College London, London, UK
2Department of Gastroenterology, Ealing Hospital, London North West University Healthcare NHS Trust, Southall, UK
3National Heart and Lung Institute, Imperial College London, London, UK

Tóm tắt

AbstractWe propose a new hypothesis that the established drug pentoxifylline deserves attention as a potential repurposed therapeutic for COVID‐19. Pentoxifylline is an immunomodulator with anti‐inflammatory properties. It is a nonselective phosphodiesterase inhibitor and through Adenosine A2A Receptor‐mediated pathways reduces tumor necrosis factor alpha, interleukin 1, interleukin 6, and interferon gamma and may act to reduce tissue damage during the cytokine storm host response to SARS‐CoV‐2 infection. This agent has been used clinically for many years and has a favorable profile of safety and tolerability. Pre‐clinical data support pentoxifylline as effective in cytokine‐driven lung damage. Clinical studies of pentoxifylline in radiation and cytokine‐induced lung damage in humans are positive and consistent with anti‐inflammatory efficacy. Pentoxifylline is a readily available, off‐patent and inexpensive drug, suitable for large‐scale use including in resource‐limited countries. Current trials of therapeutics are largely focused on the inhibition of viral processes. We advocate urgent randomized trials of pentoxifylline for COVID‐19 as a complementary approach to target the host responses.

Từ khóa


Tài liệu tham khảo

10.1001/jama.2020.1585

10.1016/j.jinf.2020.03.037

10.1016/S0140-6736(20)30183-5

10.1016/j.chom.2020.04.009

10.1016/S0140-6736(20)31022-9

Arnold JD, 2020, Tumour necrosis factor may be the central regulator of Covid‐19 protection produced by BCG vaccination, BMJ

10.1016/S0140-6736(20)30858-8

Stafford N, Pentoxifylline is an inexpensive and widely available oral anti‐tumour necrosis factor agent for prevention or treatment of cytokine storm in COVID‐19, BMJ

10.1002/j.1552-4604.1985.tb02796.x

10.3390/jcm8030287

10.1096/fj.13-228122

10.1378/chest.124.4.1526

10.1016/j.yexmp.2014.05.009

10.1093/ndt/gfh127

10.1016/S0360-3016(03)01444-5

10.1053/rmed.2001.1255

10.1056/NEJMoa1412278

10.1164/ajrccm.159.2.9804085

10.1007/s10787-006-0002-5

10.1615/CritRevEukarGeneExpr.v20.i2.10

10.1016/S2213-2600(20)30243-5

10.1172/JCI86802

10.1056/NEJMoa2015432

10.1016/j.mehy.2020.109988

10.1056/NEJMe2012924

10.1097/SHK.0b013e3181cdc3e2

10.3390/cells9030785

Ratajczak MZ, 2020, SARS‐CoV‐2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells, Leukemia, 1, 1

10.1055/s-0040-1710317

Thông tin
Thông tin xuất bản

Pharmacology Research and Perspectives

Tập 8 Số 4

Thông tin tác giả